IASLC WCLC 2020: Addition of sintilimab to pemetrexed and platinum improved progression-free survival in NSCLC
The interim analysis of ORIENT-11, a phase III double-blind randomised trial has shown a nearly…
Browsing: sintilimab
The interim analysis of ORIENT-11, a phase III double-blind randomised trial has shown a nearly…